Novavax, Inc. (NVAX) is plummeted 5.13% in the after-hours trading session at the price of $245.5 after the announcement made by the company to participate in two upcoming investor conferences. NVAX is a biotechnology company that aims to improve health globally. It designs, manufactures, and commercializes innovative vaccines to treat serious infectious diseases.
Participation in Two Upcoming September Conferences
On 9th September 2021, NVAX published about participation in two upcoming investor conferences. The discussion topic is about Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373. H.C. Wainwright 23rd Annual Global Investment Conference (Virtual) will be on 13th September 2021 at 7:00 a.m. Eastern Time (ET). Morgan Stanley 19th Annual Global Healthcare Conference (Virtual) will be on 10th September 2021 from 2:00 – 2:30 p.m. Eastern Time (ET). All recorded fireside sessions will be available on the company’s website for 90 days after the conferences.
NVAX Initiated Phase 1/2 Clinical Trial of Combination Vaccine
On 8th September 2021, NVAX announced the enrollment of the first participants in a Phase 1/2 study. The study evaluates the safety and immunogenicity of a compound vaccine using Novavax’s seasonal influenza and COVID-19 vaccines. The clinical trial mixes Novavax’s recombinant NVX-CoV2373 and NanoFlu™ vaccine candidates. Both NVX-CoV2373 and NanoFlu have previously shown strong results as standalone vaccines in Phase 3 clinical trials. The trial evaluates the safety, tolerability, and immune response to NanoFlu together with NVX-CoV2373 and Matrix-M adjuvant. Participants will have been either previously infected with the SARS-CoV-2 virus or vaccinated through an authorized vaccine eight weeks before enrollment.
President of Research and Development of NVAX, Gregory M. Glenn, commented that this study is the first of its kind to evaluate the vaccine’s potential. It aims to provoke a robust immune response simultaneously against two life-threatening diseases. These two vaccines have individually delivered outstanding results with favorable safety and tolerability profiles. The mixture of these two vaccines may lead to greater efficiencies for the healthcare system and achieve high levels of protection against COVID-19 and influenza, he added.
CDC Guidance Update for COVID-19 Clinical Trial Participants
On 30th August 2021, NVAX declared that the U.S. Centers for Disease Control and Prevention (CDC) had presented updated guidance for the vaccinated people as part of a clinical trial in the U.S. The guidance states that participants in the Novavax PREVENT-19 Phase 3 clinical trial meets the criteria to be considered fully vaccinated two weeks after their vaccination. Gregory M. Glenn remarked that Novavax praised the CDC for its continued support for COVID-19 clinical trial volunteers. CDC provided guidance updates for participants in their PREVENT-19 Phase 3 clinical trial. They are grateful to all of their clinical trial participants who have helped create a safer future for all.
